| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5599654 | Atherosclerosis | 2017 | 9 Pages |
Abstract
Notwithstanding a marked rise in HDL-C, evacetrapib did not improve endothelial function, while anacetrapib impaired it, suggesting that CETP inhibition does not provide vascular protection. Anacetrapib exerts unfavorable endothelial effects beyond CETP inhibition, which may explain the neutral results of large clinical trials in spite of increased HDL-C.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Branko Simic, Pavani Mocharla, Margot Crucet, Elena Osto, Adelheid Kratzer, Simona Stivala, Susan Kühnast, Thimoteus Speer, Petia Doycheva, Hans M. Princen, Jose W. van der Hoorn, J. Wouter Jukema, Hector Giral, Anne Tailleux, Ulf Landmesser,